Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus VALSARTAN HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus VALSARTAN HYDROCHLOROTHIAZIDE.
FILSPARI vs VALSARTAN; HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
200 mg orally once daily, with or without food.
80-320 mg valsartan / 12.5-25 mg hydrochlorothiazide once daily orally, titrated based on blood pressure response.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Valsartan: terminal half-life is approximately 6 hours. Hydrochlorothiazide: terminal half-life ranges from 5.6 to 14.8 hours, with an average of about 8 hours; prolonged in renal impairment.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Valsartan: primarily excreted unchanged in feces (70%) via biliary elimination, with renal excretion accounting for about 30% (mostly unchanged). Hydrochlorothiazide: eliminated by renal excretion, with approximately 95% of the absorbed dose excreted unchanged in urine via tubular secretion.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB